Lauren Santye, Assistant Editor

Tracking unstable chromosomes allows scientists to peer into the evolution of NSCLC.

Top news of the day from across the health care landscape.

Keytruda found to improve the overall response rate in pediatric and adult patients with cHL.

Pembrolizumab approved for adults and pediatric patients with refractory classical Hodgkin lymphoma.

Study found no statistically significant differences when switching from biologic to biosimilar.

Study examines how bacteria in the digestive tract might increase or decrease response to cancer drugs.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses how specialty pharmacists can help patients manage adverse events from their treatment regimen.

Top news of the day from across the health care landscape.

Laquinimod fails to outperform placebo in patients with relapsing-remitting MS.

Top news of the day from across the health care landscape.

Gregory R. Morris, chief commercial officer at VirMedica, discusses the eAccess program for specialty pharmacies.

Keytruda improved overall response rate and progression free survival in NSCLC.

Pembrolizumab (Keytruda) in combination with pemetrexed and carboplatin treats patients with metastatic non-squamous non-small cell lung cancer.

Overall, postmarket safety events were significantly more frequent among biologics, psychiatric therapeutics, drugs that received accelerated approval, and those with near-regulatory deadline approval.

Legendary NBA star Kareem-Abdul Jabbar faced his toughest battle after being diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.

Findings highlight the need for continuous safety monitoring of novel therapeutics.

Safety concerns noted in a large proportion of drugs approved by the FDA.

Health care use before an initial demyelinating event suggests a measureable prodromal period in multiple sclerosis.

Top news of the day from across the health care landscape.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies help advance the goals of accountable care organizations.

New data provides insight into the safety and efficacy of the FDA-approved multiple sclerosis drug.

The study is the first to demonstrate that CRISPR/Cas9 technology may lead to an HIV cure.

Top news of the day from across the health care landscape.

Substantial proportion of patients with ulcerative colitis or Crohn’s disease achieved mucosal healing with vedolizumab.

MedChew Rx is a cannabidiol that treats pain and spasticity associated with multiple sclerosis.

Top news of the day from across the health care landscape.

Cellular mechanism may present treatment target for multiple sclerosis.

Top news of the day from across the health care landscape.

Suppressing MAFK pathway in tumor cells may slow spread of aggressive breast cancer.

Active compounds in chili peppers and cannabinoids help calm the gut.